Skip to main content
Helmholtz Munich | ©Andreas Pfohl, NOZY Films GmbH

Global Platform for the Prevention of Autoimmune Diabetes (GPPAD)

GPPAD is an European platform to identify infants with an elevated genetic risk of developing type 1 diabetes, and to perform primary prevention trials aiming to reduce the incidence of islet autoimmunity and type 1 diabetes in children.

Details about our GPPAD studies and our data-sharing and biosample-sharing policies can be found on the GPPAD website.

GPPAD is an European platform to identify infants with an elevated genetic risk of developing type 1 diabetes, and to perform primary prevention trials aiming to reduce the incidence of islet autoimmunity and type 1 diabetes in children.

Details about our GPPAD studies and our data-sharing and biosample-sharing policies can be found on the GPPAD website.

The GPPAD Coordination Center is located at Helmholtz Munich with the following structure and organizational departments:

Contact

Univ.-Prof. Dr. med. Anette-Gabriele Ziegler

Institute Director, Chair of Diabetes and Gestational Diabetes, Klinikum rechts der Isar and Technical University of Munich, Director of the Global Platform for the Prevention of Autoimmune Diabetes (GPPAD)

Heidemannstraße 1, 80939 München